Axogen, Inc. Promotes Peter J. Mariani to Executive Vice President and Chief Financial Officer
March 01 2021 - 4:01PM
Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and
marketing innovative surgical solutions for peripheral nerve
injuries, today announced the promotion of Peter J. Mariani to
Executive Vice President and Chief Financial Officer.
Mr. Mariani has served as Axogen’s Chief Financial
Officer since 2016. During this time, he has played a key role in
the execution of Axogen’s strategy and in building the foundation
for long-term growth, overseeing a number of initiatives that have
strengthened the company’s capital structure, improved management
processes, and expanded the company’s facilities and
capabilities.
“Pete’s leadership has had a meaningful impact on
our company over the past five years,” said Karen Zaderej,
chairman, CEO, and president of Axogen, Inc. “The ability to
realize the full potential of our growth opportunity is driven by
continued discipline in our business processes, resource
allocation, and the execution of our key strategic initiatives.
This expanded role recognizes Pete’s significant and ongoing
contributions to Axogen’s growth and provides an opportunity for
him to drive further improvements that support our ability to
achieve our mission.”
In his expanded role, Mr. Mariani will oversee the
company’s Quality Assurance team in addition to his current
organizational responsibilities, which include oversight of the
Finance and Accounting, Investor Relations, Information Technology,
and Program Management functions.
About AxogenAxogen (AXGN) is the
leading company focused specifically on the science, development,
and commercialization of technologies for peripheral nerve
regeneration and repair. Axogen employees are passionate about
helping to restore peripheral nerve function and quality of life to
patients with physical damage or transection to peripheral nerves
by providing innovative, clinically proven, and economically
effective repair solutions for surgeons and health care providers.
Peripheral nerves provide the pathways for both motor and sensory
signals throughout the body. Every day, people suffer traumatic
injuries or undergo surgical procedures that impact the function of
their peripheral nerves. Physical damage to a peripheral
nerve, or the inability to properly reconnect peripheral nerves,
can result in the loss of muscle or organ function, the loss of
sensory feeling, or the initiation of pain.
Axogen's platform for peripheral nerve repair
features a comprehensive portfolio of products, including Avance®
Nerve Graft, a biologically active off-the-shelf processed human
nerve allograft for bridging severed peripheral nerves without the
comorbidities associated with a second surgical site; Axoguard
Nerve Connector®, a porcine submucosa extracellular matrix (ECM)
coaptation aid for tensionless repair of severed peripheral nerves;
Axoguard Nerve Protector®, a porcine submucosa ECM product used to
wrap and protect damaged peripheral nerves and reinforce the nerve
reconstruction while preventing soft tissue attachments; Axoguard
Nerve Cap®, a porcine submucosa ECM product used to protect a
peripheral nerve end and separate the nerve from the surrounding
environment to reduce the development of symptomatic or painful
neuroma; and Avive® Soft Tissue Membrane, a processed human
umbilical cord intended for surgical use as a resorbable soft
tissue barrier. The Axogen portfolio of products is available in
the United States, Canada, Germany, United Kingdom, Spain, South
Korea, and several other countries.
Cautionary Statements Concerning
Forward-Looking StatementsThis press release contains
“forward-looking” statements as defined in the Private Securities
Litigation Reform Act of 1995. These statements are based on
management's current expectations or predictions of future
conditions, events, or results based on various assumptions and
management's estimates of trends and economic factors in the
markets in which we are active, as well as our business plans.
Words such as “expects,” “anticipates,” “intends,” “plans,”
“believes,” “seeks,” “estimates,” “projects,” “forecasts,”
“continue,” “may,” “should,” “will,” “goals,” and variations of
such words and similar expressions are intended to identify such
forward-looking statements. The forward-looking statements may
include, without limitation, statements related to the
expected impact of COVID-19 on our business, statements
regarding our growth, product development, product potential,
financial performance, sales growth, product adoption, market
awareness of our products, data validation, our assessment of our
internal controls over financial reporting, our visibility at and
sponsorship of conferences and educational events. The
forward-looking statements are and will be subject to risks and
uncertainties, which may cause actual results to differ materially
from those expressed or implied in such forward-looking statements.
Forward-looking statements contained in this press release should
be evaluated together with the many uncertainties that affect our
business and our market, particularly those discussed under Part I,
Item 1A., “Risk Factors,” of our Annual Report on Form 10-K, as
amended on Form 10-K/A, for the fiscal year ended December 31,
2020, as well as other risks and cautionary statements set forth in
our filings with the U.S. Securities and Exchange Commission.
Forward-looking statements are not a guarantee of future
performance, and actual results may differ materially from those
projected. The forward-looking statements are representative only
as of the date they are made and, except as required by applicable
law, we assume no responsibility to publicly update or revise any
forward-looking statements, whether as a result of new information,
future events, changed circumstances, or otherwise.
Contact:Axogen, Inc.Peter J. Mariani, Chief
Financial
Officerpmariani@axogeninc.comInvestorRelations@AxogenInc.com
Axogen (NASDAQ:AXGN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Axogen (NASDAQ:AXGN)
Historical Stock Chart
From Apr 2023 to Apr 2024